Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials Rebaz M. Ali, Karukh K. Mohammed, Sasan M. Ahmed, Kayhan A. Najar, Mohammed Q. Mustafa, Zanyar K. Hama, Shadan A. Hamad, Maria A. Rasool and 4 more Introduction Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCLC) after progression on platinum-based therapy. This meta-analysis evaluated the efficacy and safety of tarlatamab as monotherapy and in combination… 2025 5,636 reads 1 citation doi:10.58742/bmj.v4i1.216 Full text PDF XML Read abstract — read the abstract for Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials Review Articles Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials Rebaz M. Ali, Karukh K. Mohammed, Sasan M. Ahmed, Kayhan A. Najar, Mohammed Q. Mustafa, Zanyar K. Hama, Shadan A. Hamad, Maria A. Rasool and 4 more IntroductionTarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCLC) after progression on platinum-based therapy. This meta-analysis evaluated the efficacy and safety of tarlatamab as monotherapy and in combination regimens in the treatment of SCLC. MethodsA systematic review and meta-analysis were conducted in accordance with PRISMA 2020 guidelines. PubMed/MEDLINE and EMBASE were searched from inception through September 2025 to identify clinical trials evaluating tarlatamab in SCLC. Eligible studies reported quantifiable efficacy and/or safety outcomes. Random-effects models were used to pool objective response rate (ORR) and disease control rate (DCR), and Kaplan–Meier methods were applied to assess survival outcomes. ResultsSeven clinical trials involving 1,247 patients with advanced SCLC were included. The pooled ORR was 0.42 (95% CI 0.31–0.54), with response rates ranging from 21–47% in monotherapy studies and up to 48% in combination regimens. Across six studies, pooled DCR was 0.48 (95% CI 0.31–0.66), with DCR reaching up to 87% in combination settings. Median progression-free survival ranged from 3.5 to 5.6 months, while median overall survival ranged from 13.2 to 25.3 months. Pooled time-to-event analyses demonstrated significant reductions in the risk of disease progression and death. Grade 3 and grade 4 adverse events occurred in 5.4% and 1.4% of patients, respectively, although safety reporting was incomplete in several studies. ConclusionTarlatamab demonstrates clinically meaningful antitumor activity with an acceptable safety profile in heavily pretreated SCLC. These findings support DLL3-targeted therapy as a promising treatment strategy and warrant further prospective studies to define its optimal role in the evolving SCLC treatment landscape. Keywords Targeted therapy · Immunotherapy · Second-line therapy · First-line therapy · Delta-like ligand 3 · Efficacy and safety All subjects Barw Medical Journal. 2025;3(5):42–51 Read the article PDF XML
Role of Durvalumab (Anti-PD-L1) in the Management of Mesothelioma: A Systematic Review of the Current Literature Sami S. Omar, Rebaz Haji Ali, Shalaw H. Abdullah, Dlsoz M. Hussein, Belan Mikaeil M. Radha, Alaa B. Latif, Shano M. Ali, Dilan S. Hiwa and 11 more Abstract Introduction Mesothelioma is a rare and rapidly advancing tumor that usually emerges on the mesothelial surfaces of the pleura or peritoneum. Despite being a well-recognized rare disease for decades, the only approved primary treatment protocol has been platinum-based treatments plus pemetrexed, whether or… 2023 854 reads 1 citation doi:10.58742/peq00z60 Full text PDF XML Read abstract — read the abstract for Role of Durvalumab (Anti-PD-L1) in the Management of Mesothelioma: A Systematic Review of the Current Literature Review Articles Role of Durvalumab (Anti-PD-L1) in the Management of Mesothelioma: A Systematic Review of the Current Literature Sami S. Omar, Rebaz Haji Ali, Shalaw H. Abdullah, Dlsoz M. Hussein, Belan Mikaeil M. Radha, Alaa B. Latif, Shano M. Ali, Dilan S. Hiwa and 11 more IntroductionMesothelioma is a rare and rapidly advancing tumor that usually emerges on the mesothelial surfaces of the pleura or peritoneum. Despite being a well-recognized rare disease for decades, the only approved primary treatment protocol has been platinum-based treatments plus pemetrexed, whether or not bevacizumab is administered. Immunotherapy-based immune checkpoint inhibitors demonstrated a promising antitumor efficacy in a variety of cancer types. This is a systematic review of the current role of durvalumab in the management of this condition. MethodsA systematic search was carried out through the databases and search engines. Regardless of study design, line of therapy, mode of therapy, or Eastern Cooperative Oncology Group (ECOG) performance status, studies that primarily focused on the outcomes of treating this disease with durvalumab were eligible for inclusion. After the initial and full-text screenings, five studies were reviewed. ResultsThe median age of the total 235 patients was 66.9 years. Males comprised 174 (74.04%) of the cases, with 61 (25.95%) cases being female. The Epithelioid mesothelioma subtype accounted for 194 (82.55%) of the patients. Durvalumab, in combination with pemetrexed cisplatin/carboplatin as therapy, was used in 109 (48.38%) cases. Durvalumab and tremelimumab were used in the treatment of 40 (17.02%) cases, of which 17 (7.23%) had retreatment with both immunotherapies. Among the patients who underwent durvalumab treatment, 69 (29.36% ) of the individuals previously received carboplatin/pemetrexed and cisplatin/pemetrexed. ConclusionDurvalumab can be utilized as an effective alternative for malignant pleural mesothelioma treatment, providing positive results and acceptable safety profiles. Keywords Durvalumab · Immune checkpoint inhibitors · Malignant mesothelioma · Second line · Immunotherapy All subjects Barw Medical Journal. 2023 Read the article PDF XML
